Notably, NLRP3 is associated with myocardial injuries, atherosclerosis, and diabetes mellitus [57]; high glucose stimulates NLRP3 expression thorough inhibition of its ubiquitinization in human cells [57]; therefore, we can speculate that hyperglycemia could enhance cardiotoxicity and responsiveness to ipilimumab through the NLRP3 complex. Here, NLRP3 is linked to Hyperglycemia.